[123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys

[¹²³I]FP-CIT (N-ω-fluoropropyl-2β-carbomethoxy-3β-{4-iodophenyl}tropane), a radioiodinated cocaine analogue, was evaluated as an agent for the in vivo labeling of dopamine (DA) transporters by biodistribution studies in rats and by single photon emission computed tomography (SPECT) studies in unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)–lesioned monkeys. In rats, intravenous injection of [¹²³I]FP-CIT resulted in high accumulation of radioactivity in the striatum. Less pronounced uptake was seen in brain areas with high densities of serotonergic uptake sites. While striatal uptake of radioactivity after injection of [¹²³I]FP-CIT was displaced significantly by GBR12,909 but not by fluvoxamine, the opposite was observed in brain areas known to be rich of serotonin transporters. Monkeys which were unilaterally treated with neurotoxic doses of MPTP showed severe loss of striatal [¹²³I]FP-CIT uptake at the side of treatment. The results of this study indicate that [¹²³I]FP-CIT, although not being a selective radioligand, binds specifically to the striatal DA transporter in vivo and thus suggest that [¹²³I]FP-CIT promises to be a suitable radioligand for SPECT imaging of DA transporters in humans. Synapse 27:183–190, 1997. © 1997 Wiley-Liss, Inc.     

Distribution of α-adrenergic, β-adrenergic and dopaminergic receptors in discrete hypothalamic areas of rat

Catecholamine receptor binding sites were measured in discrete hypothalamic nuclei or regions as well as in certain extrahypothalamic areas of the adult male rat. For each assay, discrete areas were microdissected from frozen tissue sections and pooled from several animals. Specific high affinity binding sites were assessed at fixed ligand concentrations for [³H]p-aminoclonidine (PAC) and [³H](2-C 2′,6′-(CH₃O)₂ phenoxyethylamino)-methylbenzodioxan (WB-4101) for α-adrenergic receptor sites, for [³H]dihydroalprenolol (DHA) for β-adrenergic receptor sites, and for [³H]2-amino-6, 7-dihydroxy-1,2,3,4-tetrahydronaphtalene (ADTN) and [³H]spiroperidol in the presence of cinanserin for dopaminergic receptor sites.Regional variations in [³H]WB-4101 binding were relatively small in magnitude, with most hypothalamic and extrahypothalamic areas possessing between 60 and 90% of the binding in frontal cortex. [³H]PAC binding showed a wider range of binding density across brain areas than did [³H]WB-4101, but, in general, variations in [³H]PAC binding paralleled those in [³H]WB-4101 binding. In hypothalamus, binding was characterized as being predominantly to α₁-receptors in the of [³H]WB-4101 and to α₂-receptors in the case of [³H]PAC. The medial hypothalamic areas exhibited a somewhat higher density of these α-adrenergic sites than did the lateral hypothalamus (perifornical hypothalamus and medial forebrain bundle). Also, the ratio of [³H]PAC to [³H]WB-4101 binding differed in different hypothalamic areas, ranging from 1.5:1 to 4:1. The median eminence was exceptional in that it contained appreciable [³H]PAC but no significant [³H]WB-4101 binding sites at the radioligand concentrations tested. Binding of [³H]DHA to β-adrenergic receptors varied over approximately a 3-fold range in the different hypothalamic areas, with binding highest in the medial forebrain bundle and the medial preoptic area, and lowest in the periventricular, dorsomedial and posterior hypothalamic nuclei, the median eminence and the zona incerta. The ratio of β-adrenergic to α-adrenergic binding sites was generally lower in the medial than in the lateral hypothalamic areas and higher in the extrahypothalamic areas examined than in the hypothalamus. With regard to [³H]spiroperidol and [³H]ADTN binding to dopaminergic sites, the striatum, nucleus accumbens and olfactory tubercle showed a greater density of [³H]spiroperidol than of [³H]ADTN sites, in contrast to the hypothalamus where [³H]ADTN binding was more predominant. Within the hypothalamus, [³H]ADTN binding was relatively uniform, while [³H]spiroperidol binding was quite high in four hypothalamic areas (lateral perifornical area, medial forebrain bundle, paraventricular and dorsomedial nuclei), intermediate in the median eminence and arcuate nucleus, and low or not detectable in all other hypothalamic areas.     

Long-term modulation of presynaptic 5-HT-output: Experimentally induced changes in cortical 5-HT-transporter density, tryptophan hydroxylase content and 5-HT innervation density

Summary Whereas experimentally induced long-term changes of postsynaptic mechanisms of 5-HT neurotransmission have been studied in great detail, much less is currently known about the effects of certain treatments on the presynaptic components governing the output of 5-HT in individual brain regions. This contribution summarizes the results of a series of experiments on the influence of different physiologic and pharmacologic manipulations on three different parameters of 5-HT presynapses, 5-HT transporter density, tryptophan hydroxylase content, and serotonin level in the rat frontal cortex. The combined measurement of several parameters of 5-HT presynapses allows to differentiate between treatments which exclusively affect the density of 5-HT transporters (long-term food restriction), which exclusively affect the level of tryptophan hydroxylase apoenzyme (imipramine treatment of olfactory bulbectomized rats) or which cause a parallel increase (bulbectomy, chronic administration of tranylcypramine to rats with chemical lesions of their cortical 5-HT innervation) or a parallel decrease (administration of p-chloroamphetamine) of both parameters, indicating treatment-induced changes in the density of 5-HT presynapses in the frontal cortex. Each of these changes may lead to an altered output of serotonergic afferences, and may therefore act to either potentiate or to attenuate the impact of serotonin-mediated effects on the activity of local networks located in a certain brain region.     

Acute and long-term effects of 17β-estradiol on Gi/o coupled neurotransmitter receptor function in the female rat brain as assessed by agonist-stimulated [S]GTPγS binding

Estrogens exert effects on mood, mental state, memory and other central nervous system (CNS) functions by modulating neurotransmitter receptor systems in the brain. Studies were designed to investigate the effect of 17β-estradiol (E₂) on agonist-stimulated [³⁵S]GTPγS binding in membranes to assess the first step in the intracellular signal transduction cascade in a functional assay following: (1) an acute, one-time bolus subcutaneous injection, or (2) 14-day continuous exposure by a slow-release pellet implanted subcutaneously. In rats treated with E₂ acutely, the maximal response produced by activation of serotonin_1A (5-HT_1A) receptors was decreased 25% in the hippocampus, cortex, and amygdala. Similarly, acute E₂ administration desensitized 5-HT_1B and GABA_B receptors in hypothalamus and cerebellum, respectively, and cannabinoid receptors in hippocampus and cortex. Although the maximal responses were decreased, acute E₂ treatment did not alter the EC₅₀ of any of the aforementioned receptors. The incubation of membranes prepared from the cortex of ovariectomized (OVX) rats with E₂ (1 μM) in vitro did not alter 5-HT_1A or cannabinoid receptor-mediated [³⁵S]GTPγS binding. By contrast to acute treatment in vivo, 14-day E₂ administration to OVX rats did not alter the maximal responses produced by activation of 5-HT_1A, 5-HT_1B, GABA_B, or cannabinoid receptors in any of the brain regions examined. Thus, it is concluded that acute E₂ administration in vivo modulates multiple G_i/o coupled receptors in various regions of the female rat brain. Because these effects are observed only in vivo, it is concluded that cytosolic, nuclear and/or extraneuronal factors are required.     

Effect of estradiol and progesterone on rat striatal dopamine uptake sites

Striatal dopamine (DA) uptake sites labelled with [3H]GBR-12935 binding were investigated in ovariectomized (OVX) rats acutely treated with 17 beta-estradiol (E2) or progesterone (P). One injection of E2 (100 ng, SC) to OVX rats increased plasma levels of this steroid after 15 min while plasma prolactin (PRL) levels remained unchanged. The E2 injection left striatal [3H]GBR-12935 binding affinity unchanged while the maximum density increased 15 and 30 min after the injection (+24% and +18%, respectively). One injection of P (110 micrograms, SC) to OVX rats increased this steroid plasma level from 15 to 120 min while plasma PRL levels remained unchanged. [3H]GBR-12935 binding density and affinity remained unchanged up to 120 min after the injection. Thus, acutely, E2 but not P, modulated striatal DA uptake sites in OVX rats. The effect of E2 appeared in coincidence with the peak of this steroid plasma concentration. This increase was rapid and is probably nongenomic and suggests a causal effect relationship as well as a presynaptic site of action of E2.     

The binding of [3H]-5-hydroxytryptamine to homogenates of human brain

Summary The binding of [³H]-5-hydroxytryptamine ([³H]-5-HT) to homogenates of human brain has been studied. The specific binding is saturable, with a K_d (frontal cortex) of 12±2nM, and is inhibited by non-radioactive 5-HT (IC₅₀=26 nM) and D-Lysergic acid diethylamide (IC₅₀=20 nM). Specific, but not non-specific binding of [³H]-5-HT was inhibited by incubation of the homogenates at 50 °C. The binding of [³H]-5-HT across the human brain was not uniform, the highest binding being found in the substantia nigra and hippocampus, and the lowest in the thalamus and pons. The K_d of the binding sites towards 5-HT did, however, appear to be similar for the different brain regions.     

Characterization and quantitative autoradiography of [H]tryptamine binding sites in rat brain

[³H]tryptamine binds with high affinity (K_d = 9.1nM, B_max= 54fmol/mg wet wt.) to tissue sections of rat brain. The binding occurs rapidly and is reversible. Low concentrations of the β-carbolines harmaline (IC₅₀ = 25nM) and tetrahydronorharman (tetrahydro-β-carboline), IC₅₀ = 50nM) inhibit [³H]tryptamine binding. Serotonin (5-HT, IC₅₀ = 2600nM) as well as the 5-HT receptor antagonists methysergide and metergoline displace [³H]tryptamine at much higher concentrations from brain slices. The distribution of [³H]tryptamine binding sites in section of rat brain has been analyzed by quantitative autoradiography. The highest density of binding sites is found in the nucleus (n.) interpreduncularis, a slightly lower one in the locus coeruleus. Moderately labelled are the n. accumbens septi, n. septi lateralis, n. medalis habenulae, n. tractus olfactorii lateralis, the central region of the amydgala, n. caudatsu/putamen, n. reuniens and the hippocampal formation. A low density of binding sites is detected in the cerebral cortex and the subiculum. Even less binding sites are found in the n. dorsalis raphe and the substantia nigra. The pattern of distribution of [³H]tryptamine binding sites differs from that of [³H]5-HT(5-HT₁), [³H]ketanserin (5-HT₂) as well as [³H]imipramine binding sites. These data suggest unique tryptamine binding sites.     

Platelet [H]paroxetine binding in patients with OCD-related disorders

The recently introduced notion of clinical conditions being related one to another, the spectrum concept, permits the testing of the involvement of serotonergic systems in a broad range of disorders tentatively linked to obsessive–compulsive disorder (OCD) for which no pathophysiological hypotheses yet exist. We therefore compared the binding of [³H]paroxetine ([³H]Par), a ligand that specifically labels the serotonin (5-HT) transporter, in platelets of drug-free outpatients suffering from various OCD-related disorders with binding in platelets of OCD patients and healthy subjects. Diagnoses were made according to DSM-IV criteria. The most frequent diagnosis was that of body dysmorphic disorder, followed by impulse control disorder, kleptomania, Tourette’s syndrome and trichotillomania. Platelet membranes and [³H]Par binding were studied according to standardized protocols. The results, showing a similarly decreased density of [³H]Par binding sites in both patient groups as compared with healthy subjects, suggest the presence of a shared abnormality at the level of the presynaptic 5-HT transporter, probably linked to a common dimension yet to be identified.     

Striatal dopamine release stimulated by amphetamine or potassium: influence of ovarian hormones and the light-dark cycle

The release of endogenous dopamine (DA) from rat striatal tissue was studied in an in vitro superfusion system following hormonal manipulations in vivo. Progesterone treatment in estrogen-primed ovariectomized female rats potentiated DA release stimulated either by amphetamine or potassium (K⁺). In addition, the amount of striatal DA released in response to K⁺-stimulation was influenced by the light-dark cycle. We conclude that striatal DA release is modulated by ovarian hormones, and suggest that ovarian hormone modulation of presynaptic striatal DA activity may contribute to well-known estrous cycle dependent variations in some non-reproductive behaviors.     

[H]GBR 12935 labels mainly the piperazine acceptor site in the rat prefrontal cortex

The binding characteristics of [³H]GBR 12935, a ligand for the dopamine (DA) transporter, have been extensively investigated in the striatum. The present study was designed to characterize L³H]GBR 12935-binding to prefrontal cortex (PFC) in rats. This region receives a dense DA input from the ventral tegmental area and is suspected to play a major role in higher associative functions. We demonstrated high-affinity, saturable, mazindol-sensitive [³H]GBR 12935-binding in the rat PFC; however, in contrast to the striatum, such binding was inhibited by increasing concentrations of Na⁺. This fact, together with the irregular pattern of the association kinetics and the marked sensitivity of [³H]GBR 12935-binding to piperazine derivatives, indicates the possible presence of more than one [³H]GBR 12935-binding site in the PFC. Furthermore, it appears that [³H]GBR 12935 in the rat PFC labels mainly ‘the piperazine acceptor site’ and not the DA transporter.     

Oestradiol Modulation of Serotonin Reuptake Transporter and Serotonin Metabolism in the Brain of Monkeys

Serotonin (5-hydroxytryptamine; 5-HT) is an important brain neurotransmitter that is implicated in mental and neurodegenerative diseases and is modulated by ovarian hormones. Nevertheless, the effect of oestrogens on 5-HT neurotransmission in the primate caudate nucleus, putamen and nucleus accumbens, which are major components of the basal ganglia, and the anterior cerebral cortex, mainly the frontal and cingulate gyrus, is not well documented. The present study evaluated 5-HT reuptake transporter (SERT) and 5-HT metabolism in these brain regions in response to 1-month treatment with 17β-oestradiol in short-term (1 month) ovariectomised (OVX) monkeys (Macaca fascicularis). SERT-specific binding was measured by autoradiography using the radioligand [³H]citalopram. Biogenic amine concentrations were quantified by high-performance liquid chromatography. 17β-Oestradiol increased SERT in the superior frontal cortex and in the anterior cingulate cortex, in the nucleus accumbens, and in subregions of the caudate nucleus of OVX monkeys. 17β-Oestradiol left [³H]citalopram-specific binding unchanged in the putamen, as well as the dorsal and medial raphe nucleus. 17β-Oestradiol treatment decreased striatal concentrations of the precursor of 5-HT, 5-hydroxytryptophan, and increased 5-HT, dopamine and 3-methoxytyramine concentrations in the nucleus accumbens, caudate nucleus and putamen, whereas the concentrations of the metabolites 5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylacetic acid and homovanillic acid remained unchanged. No effect of 17β-oestradiol treatment was observed for biogenic amine concentrations in the cortical regions. A significant positive correlation was observed between [³H]citalopram-specific binding and 5-HT concentrations in the caudate nucleus, putamen and nucleus accumbens, suggesting their link. These results have translational value for women with low oestrogen, such as those in surgical menopause or perimenopause.     

Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors

Summary. The effects of neuroleptics have been attributed to dopamine (DA) receptor blockade; however, other neurotransmitters, in particular serotonin (5-HT), have also been implicated. In this study, we examined the effects of clozapine and haloperidol on the distribution of DA and 5-HT transporters, on endogenous DA, 5-HT and their major metabolites, and on 5-HT_1A receptors. Adult male Sprague-Dawley rats were treated with either haloperidol (1 mg/kg/day, i.p.), clozapine (20 mg/kg/day, i.p.) or saline for 21 days, and following 3 days of withdrawal, the brains were removed. Tissue levels of DA and 5-HT and their metabolites were measured by high-performance liquid chromatography in 16 brain regions, while quantitative autoradiography with [¹²⁵I]RTI-121, [³H]citalopram and [³H]8-OH-DPAT was employed to label DA transporters, 5-HT transporters and 5-HT_1A receptors, respectively. After haloperidol, densities of 5-HT transporters were increased in the dorsal insular cortex and in the ventral half of caudal neostriatum, while 5-HT_1A receptors augmented in cingulate cortex but decreased in the entorhinal area. After clozapine, [³H]citalopram labelling was increased in ventral hippocampus, ventral caudal neostriatum and nucleus raphe dorsalis, but decreased in medio-dorsal and latero-dorsal neostriatum as well as in substantia nigra. Binding of [³H]8-OH-DPAT following clozapine was decreased in frontal, parietal, temporal and entorhinal cortices but increased in the CA3 division of Ammon's horn. The changes in 5-HT transporters in nucleus raphe dorsalis and substantia nigra, as well as the 5-HT_1A receptor down-regulations caused by clozapine but not by haloperidol, may explain effects obtained with clozapine and other atypical neuroleptics. There were no modifications in densities of DA transporters, nor of tissue DA levels, after the chronic neuroleptic treatments. The results are in line with previous suggestions that a certain degree of tolerance to neuroleptics develops, in spite of profound D₁ and D₂ receptor changes that persist during the entire chronic treatment with these psychotropic agents. Received September 2, 1997; accepted July 9, 1998     

Regional differences in binding of [H]LSD and [H]L-HT in calf hippocampal slices revealed by radioautography and rapid filtration studies

Previous radioautographic experiments demonstrated that binding sites labeled by [³H]5-HT and [³H]LSD in rat brain were seen in all layers of CA1, CA4 and the dentate gyrus but not in fields CA2 and CA3 of the hippocampus. In an attempt to confirm this observation we performed binding assays on homogenates from selected areas of calf hippocampus since the small size of the rat hippocampus precluded using preparations from this animal for this purpose. Studies on homogenates from calf hippocampal regions, were done after we determined that the binding to slices in vitro was similar in the calf and rat. Binding of both [³H]5-HT and [³H]LSD by homogenates of CA1 and dentate gyrus, but not of CA3, was saturable. These studies show that the qualitative differences in binding site distribution within the calf hippocampus seen by radioautography reflect quantitative differences in the densities of binding sites revealed by the homogenate studies.     

High-affinity serotonin binding sites: Autoradiographic evidence for their location on retinal afferents in the rat superior colliculus

High affinity 5-HT binding sites (5-HT₁) were labeled in vitro on mounted rat brain slices using [³H]5-HT as a radioligand. In the first stage of experimentation, the bound radioactivity was measured on slices by liquid scintillation count in order to define the biochemical characteristics of the binding. Saturation curves were drawn, as well as association and elution curves for a 2 nM radioligand concentration. The mean affinity constant of the specific binding (K_d) was found to be 2.9 nM. In the second stage, the experimental parameters giving optimum binding were applied to the frozen slices prepared exactly as for the biochemical approach in order to investigate the effects of degeneration of retinal axon terminals on the distribution of 5-HT₁ sites in the visual upper layers of the superior colliculus. The optical densities directly measured from tritium-sensitive film clearly indicate that the ablation of one eye causes a progressive reduction in the binding in the contralateral, largely deafferented, stratum griseum superficiale (SGS); with a 24-day survival period, the reduction was about 35–40%. In the homologous region of the ipsilateral colliculus, the binding decreased by about 10–15%. It is concluded that at least two populations of 5-HT₁ binding sites coexists in the visual collicular layers, one of which is probably located on the axon terminals of retinal afferents. The present results confirm a previous hypothesis based on iontophoretic data, according to which this monoamine is involved in retino-collicular transmission. As far as the retinofugal terminal binding sites are concerned, 5-HT seems to exert a presynaptic control on visual inputs.     

Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: An autoradiographic study

This study was undertaken to investigate the effect of chronic treatment with fluoxetine, a selective serotonin uptake inhibitor used widely in the treatment of depression, on the distribution and density of 5-HT uptake sites, 5-HT₂ receptors, and vesicular amine uptake sites in rat brain. Fluoxetine (10 mg/kg i. p.) was administered daily for 21 days. The density of 5-HT uptake sites labelled by [³H]paroxetine, 5-HT₂ receptors labelled by [³H]ketanserin in presence of tetrabenazine and vesicular amine uptake sites labelled by [³H]ketanserin in the presence of mianserin were measured by quantitative autoradiography in 22 areas of rat brain, using coronal tissue sections. Chronic administration of fluoxetine produced significant increases in the density of 5-HT uptake sites in layers of frontoparietal cortex (by 32–43%), of striate cortex (by 55%), in CA1 field of hippocampus (by 111%) and in superior colliculus (by 20%). Fluoxetine treatment also resulted in upregulation of 5-HT₂ receptors in layers of frontparietal cortex (31–38%) and in CA2-3 fields of hippocampus (by 39%). The density of tetrabenazine-sensitive vesicular amine uptake sites in the caudate-putamen was also significantly increased (by 66%). The observed alterations in 5-HT uptake site and 5-HT₂ receptor densities are likely a part of adaptive neuronal changes that occur after chronic administration of fluoxetine and may be related to the antidepressant effect of the drug. © 1993 Wiley-Liss, Inc.     

SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: Pharmacological characterization of brain uptake in nonhuman primates

Single photon emission computed tomography (SPECT) studies of regional kinetic uptake and pharmacological specificity of [¹²³I] methyl 3β- (4-iodophenyl) tropane-2β-carboxylate ([¹²³I]β-CIT) were performed in nonhuman primates (n = 41). In control experiments, activity was concentrated in striatum and in hypothalamic/midbrain regions. Striatal uptake increased for 140–180 min and displayed stable levels thereafter. Striatal to cerebellar activity rations were 7.3 ± 0.9 (mean ± SEM) at 300 min. About 75% of striatal uptake was displaceable by injection of nonradioactive β-CIT. Hypothalamic/midbrain activity reached maximal levels at approximately 45 min. A slow washout phase followed this peak activity. Activities in frontal, occipital, and cerebellar regions were characterized by an early peak (20–30 min), followed by rapid washout. Displacement studies demonstrated that striatal uptake was associated with dopamine (DA) transporters, as it was displaced by GBR 12909, a selective DA uptake inhibitor, but not by citalopram, a selective serotonin (5-HT) uptake inhibitor. The inverse was true in the hypothalamic/midbrain area, suggesting that the uptake in this area was associated primarily with 5-HT transporters. Maprotiline, a selective norepinephrine uptake inhibitor, did not affect [¹²³I]β-CIT uptake. In vivo site occupancy ED₅₀ values of cocaine, 2β-carbomethoxy-3β-(4-fluorophenyl) tropane (CFT), and β-CIT were measured in the striatum with a stepwise displacement paradigm. In vivo ED₅₀ values correlated strongly with in vitro IC₅₀ values for binding to DA transporters. Infusion of high dose of L-DOPA (250 μMol/kg) failed to displace striatal [¹²³I]β-CIT binding, suggesting that the binding would not be affected by L -DOPA administration in Parkinsonian patients. However, studies performed with injection of d-amphetamine indirectly suggested that high synaptic levels of DA may compete with [¹²³I]β-CIT binding, These studies suggest that [¹²³I]β-CIT will be a useful SPECT tracer of DA and 5-HT transporters in living human brain. © 1993 Wiley-Liss, Inc.     

5-Hydroxytryptamine-sensitive [H]imipramine binding of protein nature in the human brain.: II. Effect of normal aging and dementia disorders

Recently, a high-affinity [³H]imipramine binding site of protein nature that appeared related to the 5-hydroxytryptamine (5-HT, serotonin) uptake mechanism was demonstrated in the rat brain. In a preceding paper a similar [³H]imipramine binding site of protein nature and displaceable by 5-HT was demonstrated in the human brain. Most previous [³H]imipramine binding studies of the human brain have used desipramine-sensitive binding, which appears to contain a significant amount of additional binding not related to 5-HT neurons. Therefore this study of the human brain in the normal aging, in Alzheimer's disease/senile dementia of Alzheimer type (AD/SDAT) and in multiinfarction dementia (MID) presents data on 5-HT-sensitive [³H]imipramine binding. The influence of normal aging (17–100 years) was studied in the frontal and cingulate cortices, in the putamen, caudate nucleus, amygdala and in the hippocampus. An age-related change in 5-HT-sensitive [^{3H]imipramine binding was only noted in the cingulate cortex with a 50% loss in B_max over the adult age range. In contrast, desipramine-sensitive [3H]imipramine binding studied in the frontal cortex and in the putamen showed marked increases in B_max with age which correlated with increases in K_d}. It is suggested that these increases are related to an increased binding to lipophilic membrane components not related to 5-HT neurons. The 5-HT-sensitive [³H]imipramine binding ( B_max) was reduced to 60% of control in the cingulate cortex and to 50% in the putamen in AD/SDAT. In MID there was a 50% loss of [³H]imipramine binding sites ( B_max) in the putamen, but a 30% loss in the cingulate cortex did not reach statistical significance. It is concluded that the losses of 5-HT-sensitive [³H]imipramine binding sites reflect a corresponding loss of 5-HT neurites.     

Direct effect of 17 beta-estradiol on striatum: sex differences in dopamine release

The nigrostriatal dopamine (DA) system is sexually dimorphic. In female but not male rats, striatal DA activity is modulated by gonadal steroid hormones. Ovariectomy (OVX) decreases striatal DA release and turnover. Estrogen replacement restores the response to that of the intact female in estrus. In contrast, castration (CAST) of male rats has no effect on the stimulated release of DA from striatal tissue. This report addresses the question: Dose estrogen act directly on the striatum to induce changes in DA release? Physiological concentrations of 17b?-estradiol and other steroids or a nonsteroidal estrogen analog were applied directly to striatal tissue maintained in an in vitro superfusion system. The effect of hormonal treatments on the responsiveness of striatal DA terminals to stimulation was examined in tissue from OVX females and intact and CAST male rats. The results are summarized as follows: (1) Infusion of 17b?-estradiol (p < 0.01) and diethylstilbesterol (p < 0.05) increased amphetamine (AMPH)-stimulated striatal DA release from striatal tissue of OVX female rats compared with the effect of cholesterol. 17alpha-Estradiol also tended to potentiate the striatal DA response to AMPH, but this result was not statistically significant (p < 0.062). 17b?-Estradiol had no effect on AMPH-stimulated DA release from striatal tissue of intact male rats. (2) The KCl-stimulated release of DA from striatal tissue of OVX rats exposed in vitro to 100 pg/ml 17b?-estradiol (a physiological dose) was significantly greater (p < 0.05) than the response after exposure to vehicle. In contrast, 1,000 pg/ml 17b?-estradiol produced a decrease in KCl-induced striatal DA release (p < 0.05), whereas 17alpha-estradiol (100 pg/ml or 1,000 pg/ml) did not significantly influences the response to KCl. (3) The pulsatile administration of 17b?-estradiol stimulated DA release from strital tissue of OVX females (p < 0.05; compared with tissue from an OVX group that received vehicle or CAST male rats exposed to either 17b?-estradiol or vehicle). It is concluded that with tissue from OVX rats, physiological concentrations of estrogen can act directly on striatal tissue in vitro to stimulate DA release and to increase striatal DA responsiveness to stimulation, whereas prolonged exposure or high concentrations of 17b?-estradiol decreases striatal DA responsiveness. The striatum and/or the striatal DA system are sexually dimorphic in this regard.     

Age-Related Changes in the N-Methyl- -aspartate Receptor Binding Sites within the Human Basal Ganglia

The present study examined the regional differences in dopamine transporter binding sites and NMDA receptor complex binding based on autoradiographic images obtained in postmortem sections of human normal brain tissues. In middle-aged control tissues, high and comparable levels of [³H]CFT binding were observed in the caudate nucleus, putamen, and accumbens nucleus without significant alteration along the rostrocaudal axis and ventral and dorsal parts of these nuclei. In aging normal brain tissues, dopamine binding sites for [³H]CFT were significantly reduced in the caudate nucleus, putamen, and accumbens nucleus. -[³H]Glutamate, [³H]MK-801, and [³H]glycine binding to the NMDA receptor complex was lower in aging brain tissues than in middle-aged controls. Significant correlation did occur between age and [³H]CFT binding and between age and -[³H]glutamate, [³H]MK-801, and [³H]glycine binding sites. These results demonstrate that the basal ganglia have age-associated reductions in dopamine transporter uptake and NMDA receptors. These data support hypoactive activity of the NMDA receptor complex system with advancing age. The dopamine transporter uptake and NMDA receptors appear to be vulnerable to the aging process in the basal ganglia.